ARMCX1

Across TCGA pan-cancer cohorts, ARMCX1 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ARMCX1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ARMCX1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ARMCX1 is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

CCRCC, COAD, and LSCC are the cancer types where ARMCX1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARMCX1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	−1.034	<.001	12	view →
COAD	Male	III,IV	−1.055	<.001	10	view →
LSCC	Male	II,III,IV	−0.647	<.001	8	view →
HNSC	All	All	−0.432	<.001	8	view →
PDAC	Female	All	−0.588	<.001	7	view →
LUAD	Female	All	−0.344	<.001	6	view →
OV	All	All	−0.470	.006	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ARMCX1–CCRCC

Open the CCRCC breakdown →